VolitionRx Study Shows High Accuracy for Feline Lymphoma Blood Test

VolitionRx Limited announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer.

The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and noted that veterinarians have sought a feline screening solution for years. Following the international rollout of its canine cancer test, VolitionRx indicated it has now demonstrated the technology’s effectiveness in cats and plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms.

This development matters because early detection of lymphoma in cats could significantly improve treatment outcomes and quality of life for affected animals. Traditional diagnostic methods are often delayed until symptoms become apparent, which can limit treatment options and reduce survival rates. A simple blood test that can accurately identify lymphoma without invasive procedures represents a major advancement in veterinary oncology, potentially allowing for earlier intervention and more effective management of the disease.

The implications of this announcement extend beyond veterinary medicine to the broader field of cancer detection. VolitionRx’s success in developing accurate blood-based tests for both canine and feline cancers demonstrates the potential of their epigenetic technology platform. This approach could eventually be adapted for other species or even inform human cancer detection methods. The company’s multinational operations and research facilities in Belgium, the United States, and London position them to continue advancing epigenetic science across multiple applications.

For more information about VolitionRx and their epigenetic research, visit their official website. The company’s commitment to developing simple, cost-effective blood tests for disease detection aligns with growing demand for non-invasive diagnostic tools across both human and veterinary medicine. As they complete development of the Nu.Q Vet Feline Test and prepare for distribution through established networks, this technology could soon become a standard tool in veterinary practices worldwide, fundamentally changing how feline lymphoma is detected and managed.